Evidence map›Paper›PMID 37744366›Full record

ArticleFrontiers in immunology2023

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

Zhimin Zeng, Xiaoying Qian, Fanrong Liu, Yong Wang, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Zhimin ZengDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Xiaoying QianDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Fanrong LiuDepartment of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yong WangDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yong YuanDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Chen FangDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xinwei ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Shangkun YuanDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Renfang ChenDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Biao YuDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Tong WangDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yan YinDepartment of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yong LiDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Anwen LiuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.956982.].

Indexed as

anlotinibcamrelizumabimmune checkpoint inhibitorsimmunotherapypulmonary sarcomatoid carcinomatislelizumab

Identifiers

PMID37744366
PMCPMC10512075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.